Advancing Next-Generation Psychedelic Therapeutics through Selective 5‑HT2A Activation, Precision Aerosol Delivery, and Optimized 5‑MeO-DMT Treatment Paradigms.

The psychedelic therapeutics field continues to evolve beyond classical hallucinogens toward integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds, and structured 5-MeO-DMT treatment regimens for depression. Together, these innovations illustrate a convergence toward scalable, safer, and clinically practical neuropsychiatric therapies that may reshape the future of serotonergic medicine.